Jonathan Young - Mar 1, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Mar 1, 2024
Transactions value $
$51,242
Form type
4
Date filed
3/5/2024, 05:16 PM
Previous filing
Dec 29, 2023
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $51.2K +83.3K +44.88% $0.62* 269K Mar 1, 2024 Direct F1
holding AKRO Common Stock 20K Mar 1, 2024 By EA Irrevocable Trust F2
holding AKRO Common Stock 20K Mar 1, 2024 By CM Irrevocable Trust F2
holding AKRO Common Stock 20K Mar 1, 2024 By JL Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -83.3K -100% $0.00* 0 Mar 1, 2024 Common Stock 83.3K $0.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The options are vested and currently exercisable.